CaMKII regulates pericyte loss in the retina of early diabetic mouse

Young Hee Kim1, Yoon Sook Kim, So Yun Park

  • 1Department of Anatomy and Neurobiology, School of Medicine, Brain Korea 21 Biomedical Center, Gyeongsang National University, Jinju, 660-751, Korea.

Molecules and Cells
|February 19, 2011
PubMed

Insights

Calcium/calmodulin-dependent protein kinase II (CaMKII) activation contributes to inducible nitric oxide synthase (iNOS)-related pericyte death in diabetic retinopathy. Inhibiting CaMKII reduces this cell death and may offer a potential treatment for retinal vascular lesions.

Area of Science:

  • Ophthalmology
  • Diabetology
  • Molecular Biology

Background:

  • Diabetic vascular lesions involve inducible nitric oxide synthase (iNOS).
  • Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) regulates iNOS.
  • Early-stage diabetic retinopathy involves pericyte death in the retina.

Purpose of the Study:

  • To investigate CaMKII's role in iNOS-mediated pericyte death in diabetic mouse retinas.
  • To assess the therapeutic potential of CaMKII inhibition in diabetic retinopathy.

Main Methods:

  • Western blotting for CaMKII, phospho-CaMKII, iNOS, and active caspase-3.
  • CaMKII activity assay.
  • Double immunofluorescence for iNOS and α-smooth muscle actin.
  • TUNEL assay for cell death.
  • Intravitreal injection of CaMKII inhibitor (AIP).

Main Results:

  • Diabetic retinas showed increased CaMKII, phospho-CaMKII, iNOS, active caspase-3, and CaMKII activity.
  • iNOS-positive pericytes underwent apoptosis (TUNEL assay).
  • CaMKII inhibition by AIP reduced these markers and pericyte loss.

Conclusions:

  • CaMKII activation is crucial for iNOS-related pericyte death in diabetic retinas.
  • CaMKII inactivation shows potential as a therapeutic strategy for diabetic retinopathy's vascular complications.